Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.
暂无分享,去创建一个
E. Braunwald | A. Kirtane | I. Rokos | S. Murphy | C. McCabe | C. Gibson | S. Rohrbeck | V. Menon | N. Shammas | T. Palabrica | Jeffrey Lins | S. Kazziha | P. Fish | C. Gibson | C. Mccabe
[1] R. Schiele,et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. , 2005, European heart journal.
[2] M. Gyöngyösi,et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion—results of the Austrian multi-centre randomized ReoPro-BRIDGING study , 2005 .
[3] Harlan M Krumholz,et al. Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 Analysis , 2005, Circulation.
[4] E. Antman,et al. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. , 2005, The American journal of cardiology.
[5] K. Huber,et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. , 2004, European heart journal.
[6] H. Suryapranata,et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. , 2004, European heart journal.
[7] A. Colombo,et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. , 2003, Journal of the American College of Cardiology.
[8] D. Cutlip,et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. , 2003, The American journal of cardiology.
[9] C. Bode,et al. Abciximab, Eptifibatide, and Tirofiban Exhibit Dose-dependent Potencies to Dissolve Platelet Aggregates , 2003, Journal of cardiovascular pharmacology.
[10] A. Yeung,et al. Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial , 2003, Circulation.
[11] J. Boura,et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials , 2003, The Lancet.
[12] M. Noc,et al. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. , 2002, The American journal of cardiology.
[13] J. J. Griffin,et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.
[14] G. Stone,et al. Normal Flow (TIMI-3) Before Mechanical Reperfusion Therapy Is an Independent Determinant of Survival in Acute Myocardial Infarction: Analysis From the Primary Angioplasty in Myocardial Infarction Trials , 2001, Circulation.
[15] D. Cutlip,et al. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. , 2001, The American journal of cardiology.
[16] M. Morice,et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.
[17] E. Antman,et al. Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction: A TIMI 14 Substudy , 2001, Circulation.
[18] C M Gibson,et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. , 2000, Circulation.
[19] C. Gibson,et al. Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting , 1999, Annals of Internal Medicine.
[20] H. Olsson,et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. , 1999, Journal of the American College of Cardiology.
[21] A. Kastrati,et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. , 1998, Circulation.
[22] J. Burchenal,et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.
[23] R. Califf,et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. , 1997, Circulation.
[24] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.
[25] T Sandor,et al. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. , 1992, The American journal of cardiology.
[26] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.
[27] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[28] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.